The same problem was observed for folding-disease variants in other SLC6 transporters (Freissmuth et al., 2018): e.g., infantile parkinsonism/dystonia in the dopamine transporter (DAT; Kurian et al., 2009, 2011; Ng et al., 2014), epilepsy in the GABA transporter 1 (GAT1), orthostatic intolerance in the transporter for norepinephrine (NET; Hahn et al., 2002) and hyperekplexia in the glycine transporter 2 (GLYT2; Eulenburg et al., 2006; Rees et al., 2006; Arribas-González et al., 2015). Here, SLC6A3 is linked to epilepsy.